Key facts
| Price (PPV) | 153.60 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | irbesartanhydrchlorothiazide |
| Class | Agents acting on the renin-angiotensin system |
| ATC code | C09DA04 |
| Manufacturer | SOTHEMA |
| Presentation | Boite de 28 |
| Nature | Médicament |
| Hospital price | 96 MAD |
| Data collected on | 9/8/2026 |
Indications
Traitement de l'hypertension artérielle essentielle lorsque l'effet d'une monothérapie reste insuffisant. Traitement initial en cas d'hypertension prononcée, lorsqu'un contrôle rapide de la pression artérielle (en termes de jours ou de semaines) est de première importance clinique.
Find an open pharmacy
On-call pharmacies near you
Same-strength alternatives — cheapest first
Co-Arapro 300 mg / 25 mg (ZENITH PHARMA) contains the same active substance as Co-Vepran 300 mg / 25 mg (Irbesartan | Hydrchlorothiazide) at the same strength, but in a different pack: Boite de 10 at 62.40 MAD, i.e. 6.24 MAD per unit against 5.49 MAD for Co-Vepran 300 mg / 25 mg. The public sale price is set by the Ministry of Health: it is identical in every pharmacy.
Same pack size
| Product | Manufacturer | Pack | PPV | Unit price | Difference |
|---|---|---|---|---|---|
| Co-Irbesar Sun 300 mg / 25 mg | SUN PHARMACEUTICALS NORTH AFRICA S.A | Boite de 28 | 153.60 MAD | 5.49 / unit | — |
| Co-Irvel 300 mg / 25 mg | AFRIC-PHAR | Boite de 28 | 153.60 MAD | 5.49 / unit | — |
| Coaprovel 300 mg / 25 mg | SANOFI AVENTIS MAROC | Boîte de 28 | 177 MAD | 6.32 / unit | — |
Other pack sizes
| Product | Manufacturer | Pack | PPV | Unit price |
|---|---|---|---|---|
| Co-Arapro 300 mg / 25 mg | ZENITH PHARMA | Boite de 10 | 62.40 MAD | 6.24 / unit |
| Co-Irvel 300 mg / 25 mg | AFRIC-PHAR | Boite de 14 | 85 MAD | 6.07 / unit |
| Co-Arapro 300 mg / 25 mg | ZENITH PHARMA | Boite de 30 | 160.90 MAD | 5.36 / unit |
| Coavacor 300 mg / 25 mg | POLYMEDIC | Boite de 30 | 160.90 MAD | 5.36 / unit |
| Irphi Plus 300 mg / 25 mg | PHI | Boite de 30 | 160.90 MAD | 5.36 / unit |
Substituting a generic is the pharmacist's decision; for medicines listed in schedules A, B and C it still requires a prescription. Public sale prices published by the Directorate of Medicines and Pharmacy, recorded on 9/8/2026.
About Co-Vepran 300 mg / 25 mg
Co-Vepran 300 mg / 25 mg belongs to the agents acting on the renin-angiotensin system therapeutic class. In Morocco, this drug is marketed by SOTHEMA and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Co-Vepran 300 mg / 25 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Co-Vepran 300 mg / 25 mg
Answers to common questions from Moroccan patients about this drug.